WO2006131649A3 - Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques - Google Patents

Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques Download PDF

Info

Publication number
WO2006131649A3
WO2006131649A3 PCT/FR2006/001297 FR2006001297W WO2006131649A3 WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3 FR 2006001297 W FR2006001297 W FR 2006001297W WO 2006131649 A3 WO2006131649 A3 WO 2006131649A3
Authority
WO
WIPO (PCT)
Prior art keywords
bioavailability
increase
fumagillin
derivatives
macrocyclic lactones
Prior art date
Application number
PCT/FR2006/001297
Other languages
English (en)
Other versions
WO2006131649A2 (fr
Inventor
Michel Alvinerie
Jacques Dupuy
Anne Lespine
Jean-Francois Sutra
Original Assignee
Agronomique Inst Nat Rech
Michel Alvinerie
Jacques Dupuy
Anne Lespine
Jean-Francois Sutra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agronomique Inst Nat Rech, Michel Alvinerie, Jacques Dupuy, Anne Lespine, Jean-Francois Sutra filed Critical Agronomique Inst Nat Rech
Priority to AU2006256616A priority Critical patent/AU2006256616A1/en
Priority to CA002611201A priority patent/CA2611201A1/fr
Priority to EP06764749A priority patent/EP1888116A2/fr
Priority to US11/917,031 priority patent/US20080200402A1/en
Priority to BRPI0611642-6A priority patent/BRPI0611642A2/pt
Priority to MX2007015504A priority patent/MX2007015504A/es
Publication of WO2006131649A2 publication Critical patent/WO2006131649A2/fr
Publication of WO2006131649A3 publication Critical patent/WO2006131649A3/fr
Priority to US12/975,410 priority patent/US20110144045A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

L'invention concerne l'utilisation de la fumagilline, et de ses dérivés analogues, en tant qu'inhibiteurs des transporteurs cellulaires, tels que les transporteurs ABC, et plus particulièrement de la P-glycoprotéine, afin d'augmenter la biodisponibilité de principes actifs susceptibles d'être utilisés dans le traitement de pathologies telles que les cancers ou les maladies parasitaires, et en particulier afin d'augmenter la biodisponibilité des lactones macrocycliques.
PCT/FR2006/001297 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques WO2006131649A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2006256616A AU2006256616A1 (en) 2005-06-08 2006-06-08 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
CA002611201A CA2611201A1 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
EP06764749A EP1888116A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
US11/917,031 US20080200402A1 (en) 2005-06-08 2006-06-08 Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones
BRPI0611642-6A BRPI0611642A2 (pt) 2005-06-08 2006-06-08 utilização da fumagilina e de seus derivados para aumentar a biodisponibilidade das lactonas macrocìclicas
MX2007015504A MX2007015504A (es) 2005-06-08 2006-06-08 Uso de fumagilina y sus derivados para aumentar la biodisponibilidad de lactonas macrociclicas.
US12/975,410 US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0505829A FR2886855B1 (fr) 2005-06-08 2005-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
FR0505829 2005-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/975,410 Division US20110144045A1 (en) 2005-06-08 2010-12-22 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones

Publications (2)

Publication Number Publication Date
WO2006131649A2 WO2006131649A2 (fr) 2006-12-14
WO2006131649A3 true WO2006131649A3 (fr) 2007-06-21

Family

ID=35064492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001297 WO2006131649A2 (fr) 2005-06-08 2006-06-08 Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques

Country Status (9)

Country Link
US (2) US20080200402A1 (fr)
EP (1) EP1888116A2 (fr)
AU (1) AU2006256616A1 (fr)
BR (1) BRPI0611642A2 (fr)
CA (1) CA2611201A1 (fr)
FR (1) FR2886855B1 (fr)
MX (1) MX2007015504A (fr)
WO (1) WO2006131649A2 (fr)
ZA (1) ZA200710600B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270799B2 (en) * 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
AU2011204267B2 (en) 2010-01-08 2015-12-03 Zafgen Corporation Fumagillol type compounds and methods of making and using same
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
NZ610569A (en) 2010-11-09 2015-06-26 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン，インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
WO2012122264A1 (fr) 2011-03-08 2012-09-13 Zafgen Corporation Dérivés d'oxaspiro[2.5]octane et analogues
US9351988B2 (en) 2011-05-02 2016-05-31 Universite De Geneve Macrocyclic lactones and use thereof
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2763671A2 (fr) 2011-10-03 2014-08-13 Zafgen, Inc. Méthodes de traitement de troubles liés à l âge
EP2804856B1 (fr) 2012-01-18 2017-03-15 Zafgen, Inc. Composés sulfones tricycliques et leurs procédés de fabrication et d'utilisation
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン，インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
CA2872876A1 (fr) 2012-05-08 2013-11-14 Zafgen, Inc. Traitement de l'obesite hypothalamique au moyen d'inhibiteurs de metap2
EP2850079B1 (fr) 2012-05-09 2018-05-02 Zafgen, Inc. Dérivés de fumigillol, procédés pour leurs préparation et leurs utilisation
CN104918615B (zh) 2012-11-05 2018-10-12 扎夫根股份有限公司 治疗肝病的方法
EP2925737B1 (fr) 2012-11-05 2017-06-14 Zafgen, Inc. Composés tricycliques à utiliser dans le traitement et/ou la lutte contre l'obésité
CA2890342A1 (fr) 2012-11-05 2014-05-08 Zafgen, Inc. Composes tricycliques et procedes de fabrication et d'utilisation associes
EP2968250B1 (fr) 2013-03-14 2019-06-19 Zafgen, Inc. Méthodes de traitement de maladie rénale et d'autres troubles
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
DK2970101T3 (en) 2013-03-14 2018-08-20 Alkermes Pharma Ireland Ltd PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES
CA2940845C (fr) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide et promedicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline
EP0658342A1 (fr) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Composition pharmaceutique antineoplastique contenant des dérivées de fumagillol
WO1996030010A2 (fr) * 1995-03-27 1996-10-03 Sanofi Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
EP0819430A1 (fr) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibiteur de métastase ou réapparition des tumeurs
EP1258248A2 (fr) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Traitement de tumeurs avec un dérivé de fumagillol et un autre agent antinéoplastique
WO2004039172A1 (fr) * 2002-10-31 2004-05-13 Szoke Annamaria Systeme d'administration par voie orale d'un medicament veterinaire et/ou systeme d'administration d'un additif alimentaire, procede de preparation et d'utilisation de ceux-ci

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
WO1994019946A1 (fr) * 1993-03-01 1994-09-15 Emory University Traitement de la keratoconjonctivite de microsporidia et d'acanthamoeba par application locale de fumagilline
EP0658342A1 (fr) * 1993-09-24 1995-06-21 Takeda Chemical Industries, Ltd. Composition pharmaceutique antineoplastique contenant des dérivées de fumagillol
WO1996030010A2 (fr) * 1995-03-27 1996-10-03 Sanofi Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
EP0819430A1 (fr) * 1996-07-17 1998-01-21 Takeda Chemical Industries, Ltd. Inhibiteur de métastase ou réapparition des tumeurs
EP1258248A2 (fr) * 2001-05-18 2002-11-20 TAP Pharmaceutical Products, Inc. Traitement de tumeurs avec un dérivé de fumagillol et un autre agent antinéoplastique
WO2004039172A1 (fr) * 2002-10-31 2004-05-13 Szoke Annamaria Systeme d'administration par voie orale d'un medicament veterinaire et/ou systeme d'administration d'un additif alimentaire, procede de preparation et d'utilisation de ceux-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRINYAEV V A ET AL: "Antitumor effect of avermectins", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 19 - 23, XP004587589, ISSN: 0014-2999 *
LESPINE A ET AL: "Role of the p-glycoprotein in the cellular efflux of macrocyclic lactones: Influence of interfering agents.", JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, vol. 26, no. Supplement 1, August 2003 (2003-08-01), & PROCEEDINGS OF THE 9TH INTERNATIONAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR VETERINARY PHARMACOLOG; LISBON, PORTUGAL; JULY 13-18, 2003, pages 161 - 162, XP008077611, ISSN: 0140-7783 *
WILHELMUS K R: "Antiparasitic drugs in ophthalmology", INTERNATIONAL OPHTHALMOLOGY CLINICS 1996 UNITED STATES, vol. 36, no. 2, 1996, pages 117 - 152, XP008077587, ISSN: 0020-8167 *

Also Published As

Publication number Publication date
BRPI0611642A2 (pt) 2010-09-28
US20080200402A1 (en) 2008-08-21
FR2886855B1 (fr) 2009-07-17
WO2006131649A2 (fr) 2006-12-14
EP1888116A2 (fr) 2008-02-20
FR2886855A1 (fr) 2006-12-15
MX2007015504A (es) 2008-03-18
CA2611201A1 (fr) 2006-12-14
ZA200710600B (en) 2009-05-27
AU2006256616A1 (en) 2006-12-14
US20110144045A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2006131649A3 (fr) Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocycliques
PL1940249T3 (pl) Nowe formulacje rozpuszczalnych w tłuszczach składników aktywnych o wysokiej biodostępności
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2007086001A3 (fr) Nouveaux dérivés de pyridine
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
WO2006013441A3 (fr) Utilisation de bacteries probiotiques dans la preparation de compositions topiques destinees a la protection de la peau
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2005123076A3 (fr) Compositions pharmaceutiques
WO2006099169A3 (fr) Nouvelles compositions de liposomes
WO2006060515A3 (fr) Systeme permettant d'ameliorer l'absorption percutanee d'agents benefiques pour la peau
WO2006124698A3 (fr) Traitement au dronabinol de nausees et vomissements induits par chimiotherapie differee
WO2006075256A3 (fr) 9a-carbamoyl-y-aminopropyl- et 9a-thiocarbamoyl-y-aminopropyl-azalides a activite anti-paludique
WO2006021001A3 (fr) Derives de polynorbornene amphiphiles et leurs methodes d'utilisation
WO2007067784A3 (fr) Compositions liposomales
WO2009038095A1 (fr) Composition comprenant de la sésamine et de la vitamine b1
WO2011076209A3 (fr) Composition pharmaceutique comprenant un mélange de solvants et un dérivé de la vitamine d ou analogue
WO2009059755A3 (fr) Nouveaux conjugués de neurturine pour une utilisation pharmaceutique
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
WO2007086943A3 (fr) Conjugués de la wortmannine et utilisations de ceux-ci
WO2006053882A3 (fr) Formulations de benzothiazole et utilisation associee
HK1120417A1 (en) Stable nanoparticle formulations
AU2003290127A1 (en) 4-amino-7,8-dihydropteridines, pharmaceutical compositions containing them and their use for the treatment of diseases which are caused by an increased nitric oxide level

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015504

Country of ref document: MX

Ref document number: 2611201

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 564101

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006256616

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006764749

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11917031

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0611642

Country of ref document: BR

Kind code of ref document: A2